Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of CMND-100 in healthy volunteers and adults with alcohol use disorder
MOH_2024-02-25_013260Phase 2Not yet recruiting
- Sponsor
- Clearmind Medicine
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 5-methoxy-2-aminoindane in alcohol use disorder (AUD) (6 arms), sponsored by Clearmind Medicine. Primary endpoints: Tolerability, Safety and 1 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
5-methoxy-2-aminoindane
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on MOH_2024-02-25_013260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-25_013260.